Literature DB >> 3104022

Species differences in pharmacokinetics and drug teratogenesis.

H Nau.   

Abstract

Interspecies differences in regard to the teratogenicity of drugs can be the result of differing pharmacokinetic processes that determine the crucial concentration-time relationships in the embryo. Maternal absorption, as well as distribution, of the drugs does not usually show great species differences. The first-pass effect after oral application is often more pronounced in animals than man (e.g., valproic acid, 13-cis-retinoic acid), although in some cases the reverse was found (e.g., hydrolysis of valpromide). Existing differences can be adjusted by appropriate choice of the administration route and measurements of drug levels. Many variables determine the placental transfer of drugs: developmental stage, type of placenta, properties of the drug. Even closely related drugs (e.g., retinoids) may differ greatly in regard to placental transfer. Maternal protein binding is an important determinant of placental transfer, since only the free concentration in maternal plasma can equilibrate with the embryo during organogenesis; this parameter differs greatly across species (e.g., valproic acid: five times higher free fractions in mouse and hamster than in monkey and man). The metabolic pattern has not yet been demonstrated to be a major cause of species differences, although recent evidence on phenytoin and thalidomide support the hypothesis that some species differences can be the result of differing activation/deactivation pathways. Laboratory animals usually have a much higher rate of drug elimination than man. Drastic drug level fluctuations are therefore present during teratogenicity testing in animals, but not to the same degree in human therapy. It must, therefore, be investigated if peak concentrations (such as for valproic acid and possibly caffeine) or the area under the concentration-time curve (AUC) (such as for cyclophosphamide and possibly retinoids) correlate with the teratogenic response. Only then is a rational and scientific basis for interspecies comparison possible. It is concluded that the prediction of the human response based on animal studies can be improved by consideration of the appropriate pharmacokinetic determinants.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3104022      PMCID: PMC1474298          DOI: 10.1289/ehp.8670113

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  100 in total

1.  Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses.

Authors:  J R Kalin; M J Wells; D L Hill
Journal:  Drug Metab Dispos       Date:  1982 Jul-Aug       Impact factor: 3.922

2.  A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations.

Authors:  H Nau; R Zierer; H Spielmann; D Neubert; C Gansau
Journal:  Life Sci       Date:  1981-12-28       Impact factor: 5.037

Review 3.  Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.

Authors:  H Nau; W Kuhnz; H J Egger; D Rating; H Helge
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 4.  The current status of attempts to predict species differences in drug metabolism.

Authors:  J Caldwell
Journal:  Drug Metab Rev       Date:  1981       Impact factor: 4.518

5.  Congenital malformations induced by infusion of sodium cyanide in the golden hamster.

Authors:  P A Doherty; V H Ferm; R P Smith
Journal:  Toxicol Appl Pharmacol       Date:  1982-07       Impact factor: 4.219

Review 6.  Toxicology, carcinogenicity, and teratogenicity of some orally administered retinoids.

Authors:  J J Kamm
Journal:  J Am Acad Dermatol       Date:  1982-04       Impact factor: 11.527

7.  Valproic acid: metabolite concentrations in plasma and brain, anticonvulsant activity, and effects on GABA metabolism during subacute treatment in mice.

Authors:  W Löscher; H Nau
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-05

8.  Transfer of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) to the mouse embryo and fetus.

Authors:  H Nau; R Bass
Journal:  Toxicology       Date:  1981       Impact factor: 4.221

9.  Embryotoxicity induced by alkylating agents. Teratogenicity of acetoxymethyl-methylnitrosamine: dose-response relationship, application route dependency and phase specificity.

Authors:  T Platzek; G Bochert; U Rahm
Journal:  Arch Toxicol       Date:  1983-01       Impact factor: 5.153

10.  Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives.

Authors:  H Nau; H Spielmann; C M Lo Turco Mortler; K Winckler; L Riedel; G Obe
Journal:  Mutat Res       Date:  1982-08       Impact factor: 2.433

View more
  33 in total

1.  Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta.

Authors:  Keiko Fujita; Yoshiko Asami; Kayoko Tanaka; Masumi Akita; Hans-Joachim Merker
Journal:  Histochem Cell Biol       Date:  2004-06-25       Impact factor: 4.304

2.  Effects of valproic acid, some of its metabolites and analogues on prenatal development of rats in vitro and comparison with effects in vivo.

Authors:  S Klug; C Lewandowski; F Zappel; H J Merker; H Nau; D Neubert
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

3.  Voluntary exercise together with oral caffeine markedly stimulates UVB light-induced apoptosis and decreases tissue fat in SKH-1 mice.

Authors:  Yao-Ping Lu; Bonnie Nolan; You-Rong Lou; Qing-Yun Peng; George C Wagner; Allan H Conney
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

4.  Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis.

Authors:  S J Oliver; S L Freeman; L G Corral; C J Ocampo; G Kaplan
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

5.  sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.

Authors:  Dan Kaufmann; Peter J West; Misty D Smith; Boris Yagen; Meir Bialer; Marshall Devor; H Steve White; K C Brennan
Journal:  Pharmacol Res       Date:  2016-11-24       Impact factor: 7.658

6.  Retinoic acid induces Sertoli cell paracrine signals for spermatogonia differentiation but cell autonomously drives spermatocyte meiosis.

Authors:  Mathilde Raverdeau; Aurore Gely-Pernot; Betty Féret; Christine Dennefeld; Gérard Benoit; Irwin Davidson; Pierre Chambon; Manuel Mark; Norbert B Ghyselinck
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

7.  The high sensitivity of the rabbit to the teratogenic effects of 13-cis-retinoic acid (isotretinoin) is a consequence of prolonged exposure of the embryo to 13-cis-retinoic acid and 13-cis-4-oxo-retinoic acid, and not of isomerization to all-trans-retinoic acid.

Authors:  G Tzimas; H Bürgin; M D Collins; H Hummler; H Nau
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

Review 8.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

9.  Tocopherols and Tocotrienols Are Bioavailable in Rats and Primarily Excreted in Feces as the Intact Forms and 13'-Carboxychromanol Metabolites.

Authors:  Kilia Y Liu; Qing Jiang
Journal:  J Nutr       Date:  2020-02-01       Impact factor: 4.798

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.